[
| E-mail
]
Contact: Amanda Harperamanda.harper2@osumc.edu
614-685-5420Ohio State University Wexner Medical Center
COLUMBUS, Ohio In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL),…
Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL
No comments:
Post a Comment